Laura Johnson
Family · Grants Pass, ORNPI 1023348430
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,338 of the $2,702 with a category attached, or 86.5%. It is spread thinly across 26 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 112 payments — averaging $24.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$348
- Novo Nordisk$318
- AbbVie$314
- AstraZeneca$233
- Johnson & Johnson$203
- Lilly USA, LLC$165
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,33887%
- Education$36513%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 6 | $348 |
| Novo Nordisk | 13 | $318 |
| AbbVie | 15 | $314 |
| AstraZeneca | 14 | $233 |
| Johnson & Johnson | 11 | $203 |
| Lilly USA, LLC | 8 | $165 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $165 |
| Bayer | 6 | $157 |
| Merz North America, Inc. | 1 | $150 |
| Amgen | 5 | $101 |
| Biohaven Pharmaceuticals, Inc. | 1 | $68 |
| Exact Sciences | 3 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| Vanda Pharmaceuticals Inc. | 3 | $53 |
| Tactile Systems Technology Inc | 2 | $46 |
| Lundbeck LLC | 1 | $35 |
| GSK | 2 | $34 |
| Tempus AI, Inc | 1 | $32 |
| Boehringer Ingelheim | 2 | $29 |
| Mylan Specialty L.p. | 2 | $27 |
| Corium, LLC | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Grifols USA, LLC | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$150
How this compares
$2,702 in reported general payments places this provider in the 95th percentile of 1,130 family providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 92 | $109,584 |
| OzempicSemaglutide | 36 | $48,114 |
| FarxigaDapagliflozin Propanediol | 35 | $45,389 |
| JardianceEmpagliflozin | 25 | $26,590 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $23,940 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $22,746 |
| TrulicityDulaglutide | 21 | $19,977 |
| Buprenorphine | 49 | $16,258 |
| MyrbetriqMirabegron | 11 | $12,488 |
| XareltoRivaroxaban | 16 | $9,803 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $7,768 |
| Pregabalin | 71 | $6,478 |
| Potassium Chloride | 156 | $5,838 |
| BelsomraSuvorexant | 13 | $5,642 |
| PremarinEstrogens, Conjugated | 13 | $5,356 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $16 | $114,940105 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $233 | $69,32951 claims |
| Novo NordiskOzempic | $318 | $48,11436 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $34 | $30,51431 claims |
| Boehringer IngelheimJardiance | $29 | $26,59025 claims |
| Lilly USA, LLCTrulicity | $165 | $19,97721 claims |
| Astellas Pharma US IncMyrbetriq | $348 | $12,48811 claims |
| Johnson & JohnsonXarelto | $203 | $9,80316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,130 family providers in Oregon.
Other family in Grants Pass
- Nicole ParrottaGrants Pass$3K
- Rachel PangilinanPortland$103K
- Jodeanna SweeneyCentral Point$45K
- Lani DoserPortland$45K
- David ArnopoleMedford$38K
- Heather HermanCorvallis$34K
- Amy BartramOregon City$33K
- Leah GaedekePortland$26K
- Bobbi Lee RothTualatin$23K
- Susan ToftePortland$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.